Literature DB >> 2049226

DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin.

E Ferrazzi1, J M Woynarowski, A Arakali, D E Brenner, T A Beerman.   

Abstract

This study assessed the ability of major metabolites of two types of anthracycline antibiotics, doxorubicin and idarubicin (4-demethoxydaunorubicin) to damage DNA in mouse fibrosarcoma 935.1 cells. Since DNA lesions by anthracyclines may be mediated by topoisomerase II, we also characterized the ability of the drugs to inhibit this enzyme. The C-13 alcohol and aglycone metabolites of doxorubicin and idarubicin were compared to the parent drugs in terms of induction of DNA single strand breaks measured by filter elution. In whole cells, the maximal DNA strand breakage induced by the C-13 alcohol metabolites was similar to that of their respective parent drugs. In isolated nuclei, however, the alcohol metabolites were two times more potent than the parent drugs. The aglycone metabolites produced very little damage in either whole cells or nuclei. The doxorubicin compounds differed markedly from idarubicin drugs in the way their ability to induce DNA breaks was related to cytotoxic activity. Doxorubicin and doxorubicinol cytotoxic effects (50% cell growth inhibition at 0.2 and 4 microM, respectively) coincided (in terms of drug concentrations) with the induction of significant breakage of cellular DNA. In contrast, the concentrations of idarubicin and idarubicinol needed to produce 50% growth inhibition (0.005 and 0.006 microM, respectively) were about 20 times lower than drug levels that induced significant DNA damage. All six compounds inhibited the catalytic activity of isolated topoisomerase II. While the alcohol metabolites produced this inhibition at concentrations similar to those of their parent drugs (5-10 microM), the aglycones were again much less active.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049226     DOI: 10.3727/095535491820873308

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  13 in total

1.  Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.

Authors:  W Kang; M Weiss
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 2.  Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

3.  Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal.

Authors:  Shulin Xiang; Robert T Dauchy; Adam Hauch; Lulu Mao; Lin Yuan; Melissa A Wren; Victoria P Belancio; Debasis Mondal; Tripp Frasch; David E Blask; Steven M Hill
Journal:  J Pineal Res       Date:  2015-04-20       Impact factor: 13.007

4.  Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.

Authors:  F Gieseler; H Biersack; T Brieden; J Manderscheid; V Nüssler
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

5.  Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.

Authors:  Mandeep Atwal; Rebecca L Swan; Chloe Rowe; Ka C Lee; David C Lee; Lyle Armstrong; Ian G Cowell; Caroline A Austin
Journal:  Mol Pharmacol       Date:  2019-08-09       Impact factor: 4.436

6.  Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.

Authors:  Anselm Morell; Youssif Budagaga; Dimitrios Vagiannis; Yu Zhang; Lenka Laštovičková; Eva Novotná; Andrew Haddad; Melodie Haddad; Ramon Portillo; Jakub Hofman; Vladimír Wsól
Journal:  Arch Toxicol       Date:  2022-08-16       Impact factor: 6.168

7.  DNA fragmentation as a consequence of cell cycle traverse in doxorubicin- and idarubicin-treated human lymphoma cells.

Authors:  P J Smith; C Rackstraw; F Cotter
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

8.  The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.

Authors:  D Kostrzewa-Nowak; M J I Paine; C R Wolf; J Tarasiuk
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

9.  Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.

Authors:  Jatin J Shah; Robert Z Orlowski; Sheeba K Thomas
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

Review 10.  Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.

Authors:  Derek W Edwardson; Rashmi Narendrula; Simon Chewchuk; Kyle Mispel-Beyer; Jonathan P J Mapletoft; Amadeo M Parissenti
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.